Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

(ALNY, WINN, CLNO, LSCC, CMVT) Featured Stock by Stock-PR.com

|Includes:Alnylam Pharmaceuticals, Inc. (ALNY), LSCC, WINN

Stock-PR Reporting

stockpr_logo-site

 

FREE Daily Stock Alerts From Stock-PR.com

chartstockalert



http://pennyomega.com/img/stwnov16.png

http://pennyomega.com/img/alny.jpg

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Sylentis, S.A., a Spanish bio-pharmaceutical company devoted to the research and development of new therapies based on RNAi, announced that Alnylam has granted Sylentis a non-exclusive option for a new target-specific InterfeRx™ license. This license would enable the discovery, development, and commercialization of a synthetic siRNA directed towards an undisclosed target for the treatment of glaucoma. Sylentis’ program is currently in a Phase I/II clinical trial. Upon Sylentis’ exercise of this option, Alnylam would receive upfront and milestone payments, as well as royalties on sales of products covered by the licensing agreement. Additional financial details were not disclosed. Sylentis is a wholly owned subsidiary of Grupo Zeltia.

“We are pleased to be granting Sylentis a new InterfeRx license, thereby enabling their efforts with access to Alnylam intellectual property which we believe is critical for the development and commercialization of RNAi therapeutics,” said Laurence Reid, Ph.D., Senior Vice President and Chief Business Officer of Alnylam. “The agreement with Sylentis represents continued progress with our InterfeRx program, an important part of our overall strategy to create value today by leveraging our intellectual property portfolio.”

Alnylam created the InterfeRx licensing program to grant licenses under its intellectual property to biotechnology and pharmaceutical companies wishing to pursue RNAi therapeutics against specific targets outside Alnylam's core strategic interests. To date, a total of six companies are InterfeRx licensees; the license grants cover fourteen active target programs including four in clinical development. In addition to Sylentis, Alnylam's InterfeRx licensees include Calando Pharmaceuticals, Inc., Tekmira Pharmaceuticals Corporation, Quark Pharmaceuticals, Inc., GeneCare Research Institute Co., Ltd., and, under an option agreement, Benitec Ltd.

RNAi (RNA interference) is a revolution in biology, representing a breakthrough in understanding how genes are turned on and off in cells, and a completely new approach to drug discovery and development. Its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so,” and represents one of the most promising and rapidly advancing frontiers in biology and drug discovery today which was awarded the 2006 Nobel Prize for Physiology or Medicine. RNAi is a natural process of gene silencing that occurs in organisms ranging from plants to mammals. By harnessing the natural biological process of RNAi occurring in our cells, the creation of a major new class of medicines, known as RNAi therapeutics, is on the horizon. Small interfering RNAs (siRNAs), the molecules that mediate RNAi and comprise Alnylam’s RNAi therapeutic platform, target the cause of diseases by potently silencing specific mRNAs, thereby preventing disease-causing proteins from being made. RNAi therapeutics have the potential to treat disease and help patients in a fundamentally new way.

Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases, including ALN-TTR for the treatment of transthyretin-mediated amyloidosis (ATTR), ALN-PCS for the treatment of severe hypercholesterolemia, ALN-HPN for the treatment of refractory anemia, and ALN-APC for the treatment of hemophilia.

 

More about ALNY at www.alnylam.com.

Read full article at: http://stock-pr.com/?p=20718

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

**************************************************************

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Stock-PR.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold Stock-PR.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://stock-pr.com/disclaimer).Crown Equity Holdings Inc. (OTCPK:CRWE) is a media-advertisement and newswire company.Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares of 144 restricted stocks from the company for 12 months of media advertisement and IR services and 4,000,000 shares of 144 restricted stocks from the company for management fee through end of June for Cleantech Transit, Inc. (OTCPK:CLNO).

Stocks: ALNY, WINN, LSCC